{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:44:26Z","timestamp":1777877066040,"version":"3.51.4"},"reference-count":40,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100008530","name":"Fondo Europeo de Desarrollo Regional","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII), Ministry of Health, Spain","award":["Fondo de Investigaciones Sanitarias: PI18\/01188, P"],"award-info":[{"award-number":["Fondo de Investigaciones Sanitarias: PI18\/01188, P"]}]},{"name":"Instituto de Salud Carlos III (ISCIII), Ministry of Health, Spain","award":["Red de Investigaci\u00f3n en Inflamaci\u00f3n y Enfermedad"],"award-info":[{"award-number":["Red de Investigaci\u00f3n en Inflamaci\u00f3n y Enfermedad"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Musculoskeletal"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Janus kinase inhibitors (JAKi) are effective treatments for chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib are pan-JAK inhibitors, while upadacitinib and filgotinib are JAK1-selective inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to compare retention rates between JAKi classes and identify predictors of discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective observational study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively evaluated patients with CIA (Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), and Spondyloarthritis (SpA)) treated with JAKis from 2017 to 2024. The independent variable was JAKi class (pan-JAK inhibitors\/JAK1-selective inhibitors). Retention was assessed using Kaplan\u2013Meier estimates, and predictors of discontinuation were evaluated through Cox multivariable regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The study included 181 patients (83% women; median age 56). Diagnoses were RA (84%), PsA (9%), and SpA (7%). A total of 227 JAKi treatment courses were analyzed: 96 JAK1-selective inhibitors and 131 pan-JAK inhibitors. Overall, 118 courses (52%) were discontinued (55% inefficacy; 42% adverse events). The discontinuation incidence rate (IR) was 35.5 per 100 patient-years, with 50% stopping treatment within 1.65\u2009years. Discontinuation was more frequent in women, patients with cardiovascular (CV) disease or risk factors, and in PsA compared to RA. Discontinuation rates were lower for JAK1-selective inhibitors (IR: 28.6; 95% confidence interval (CI): 20.5\u201339.8) versus pan-JAK inhibitors (IR: 39.6; 95% CI: 31.9\u201349.1). Multivariate analysis confirmed that pan-JAK inhibitors, female sex, PsA, CV disease, prior targeted biological and synthetic disease-modifying drugs exposure, and leflunomide co-treatment increased the risk of discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pan-JAK inhibitors may have higher discontinuation rates than JAK1-selective inhibitors in real-world CIA patients. Clinical characteristics and comorbidities should guide JAKi selection to optimize long-term treatment retention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1759720x251393130","type":"journal-article","created":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T10:56:53Z","timestamp":1763031413000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7142-0545","authenticated-orcid":false,"given":"Leticia","family":"Leon","sequence":"first","affiliation":[{"name":"Musculoskeletal Pathology Group, Rheumatology Department, Health Research Institute (IdISSC), Hospital Cl\u00ednico San Carlos, Madrid 28040, Spain"},{"name":"Health Sciences, UNIE Universidad, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Pablo","family":"Bermejo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Cl\u00ednico San Carlos, Health Research Institute (IdISSC), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonor","family":"Laredo","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Cl\u00ednico San Carlos, Health Research Institute (IdISSC), Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Alberto","family":"Pe\u00f1a Pedrosa","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Teresa","family":"Ben\u00edtez Gimenez","sequence":"additional","affiliation":[{"name":"Hospital Pharmacy Department, Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalifer","family":"Freites","sequence":"additional","affiliation":[{"name":"Musculoskeletal Pathology Group, Rheumatology Department, Health Research Institute (IdISSC), Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"de Miguel","sequence":"additional","affiliation":[{"name":"Musculoskeletal Pathology Group, Rheumatology Department, Health Research Institute (IdISSC), Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Abasolo","sequence":"additional","affiliation":[{"name":"Musculoskeletal Pathology Group, Rheumatology Department, Health Research Institute (IdISSC), Hospital Cl\u00ednico San Carlos, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001223"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.10.010"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209058"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.13103"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1049875"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa823"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-223850"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2008250"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1608345"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215764"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216653"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-225271"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50379-8"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0016"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.201204"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1376476"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.27584"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.108233"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"e_1_3_4_24_2","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios Bolet\u00edn Mensual de la AEMPS Sobre Medicamentos de USO Humano del Mes de Noviembre de 2019. AEMPS 2019. https:\/\/www.aemps.gob.es\/."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(95)00510-2"},{"key":"e_1_3_4_27_2","volume-title":"Applied categorical data analysis","author":"Freeman DH","year":"1987","unstructured":"Freeman DH. Applied categorical data analysis. Dekker, New York, 1987."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0306714"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000546"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12144585"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.43188"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8672-5"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001681"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003160"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2023.2169990"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2020.1740593"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.151979"},{"issue":"8","key":"e_1_3_4_39_2","article-title":"Real-world experience with Janus kinase inhibitors in immune-mediated diseases: clinical experience of a university hospital","volume":"16","author":"Ramirez Huaranga MA","year":"2024","unstructured":"Ramirez Huaranga MA, Calvo Pascual LA, Velasco Sanchez D, et al. Real-world experience with Janus kinase inhibitors in immune-mediated diseases: clinical experience of a university hospital. Cureus 2024; 16(8): e67729.","journal-title":"Cureus"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac240"}],"container-title":["Therapeutic Advances in Musculoskeletal Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251393130","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1759720X251393130","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1759720X251393130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:40:19Z","timestamp":1777588819000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1759720X251393130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"alternative-id":["10.1177\/1759720X251393130"],"URL":"https:\/\/doi.org\/10.1177\/1759720x251393130","relation":{},"ISSN":["1759-720X","1759-7218"],"issn-type":[{"value":"1759-720X","type":"print"},{"value":"1759-7218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]},"article-number":"1759720X251393130"}}